Loading...
Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database
BACKGROUND: High-dose chemotherapy with autologous stem cell rescue (ASCR) is a key component of high-risk neuroblastoma therapy. Resources required to support patients treated with ASCR conditioning regimens [carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel)] have not been direct...
Na minha lista:
| Udgivet i: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5672623/ https://ncbi.nlm.nih.gov/pubmed/26797923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25893 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|